Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer (NCT00659724), a registered phase not stated study. The primary outcome is Ease of Use: Priming Blood Side.

2. Clinical Question

The registry describes a study of ease of use and thrombogenicity during routine hemodialysis. Its stated primary outcome focuses specifically on removing air from the blood side during priming. The rating scale distinguishes air removal without additional procedures from situations requiring knocking, clamping, extra saline, extended recirculation, or air that could not be removed.

This question is about a practical treatment procedure, rather than a patient-centered clinical outcome. Ease of priming may be relevant to how staff carry out treatment, but the record does not state how ratings were combined across treatments, how a comparison was planned, or what result was observed. Allocation is not stated, and the registry cautions that the arms are not a like-for-like control comparison. Consequently, the stated study purpose does not establish a randomized head-to-head test.

3. Trial Design

The registry record describes a completed study sponsored by Vantive Health LLC. It lists chronic kidney failure as the condition and reports enrollment of 33. The study start is recorded as 2008-03 and primary completion as 2008-05. Its stated purpose was to collect information on ease of use and thrombogenicity for the Gambro Polyflux HD-C4 Big and Fresenius Optiflux 180NR or 200NR dialyzers under routine clinical conditions for hemodialysis.

The record does not state an allocation method. It also does not give arm names, arm-level enrollment, the sequence in which devices were used, or a treatment schedule. The registry explicitly cautions that this is not a randomized comparison and that the arms are not a like-for-like control comparison. Those limitations matter when interpreting any apparent difference: a contrast between groups would not, on the information recorded, isolate the effect of the device from other differences between groups or treatment circumstances.

The primary outcome is listed as “Ease of Use: Priming Blood Side,” with a unit of number of dialyzers and a count-type parameter. The rating was intended for every study treatment/dialyzer. The registry lists 5 outcome measures, but does not provide values for the primary outcome in the registry record for this analysis. It lists 0 analyses. The protocol, detailed analysis plan, and further study procedures are not reported in the registry record.

Completion status describes the status recorded for the study; it does not by itself establish that every planned outcome was collected or that the results were analyzed. Enrollment is not the same as the number contributing to each outcome, and outcome-specific participant counts are not reported. The posted record therefore supports a description of the study’s purpose, setting, and registered primary measure, but not a detailed reconstruction of conduct or results.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Weeks 1-2: Assessment of 180NR or 200NR

Weeks 3-4: Assessment of HD-C4 Big

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Ease of Use: Priming Blood Side, measured over Priming at each treatment.

The primary endpoint is the number of dialyzers assigned to each nursing rating for ease of priming the blood side. Ratings were intended at each treatment. “Very Easy” means air was easily removed without knocking or clamping. “Acceptable” means knocking and/or clamping was needed for efficient air removal. “Difficult” means those procedures and additional saline or extended recirculation were needed. “Very Difficult” means air could not be removed.

This endpoint captures a practical aspect of dialyzer use: whether staff can remove air during blood-side priming, and what additional steps are needed. A categorical rating retains distinctions between levels of procedural effort rather than reducing all experiences to a single yes-or-no outcome. Counting dialyzers in each category can describe the distribution of ratings, if those counts are reported.

The registry does not report the observed category counts, the number of treatments contributing to each category, or a summary comparison. It also does not report how repeated ratings from a participant or dialyzer were handled. The stated unit is number of dialyzers, but the relationship between dialyzers, treatments, and participants is not detailed. These gaps limit interpretation of how the primary endpoint was summarized and how precisely it was measured.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry classifies the primary outcome as a count: the number of dialyzers in each ease-of-priming category. Count outcomes record how many observations fall into categories or occur over a defined period. They are not continuous measurements such as a mean score. In this study, the categories have an ordered practical meaning, from air removal without additional procedures through air that could not be removed. The registry does not report whether the categories were analyzed as separate counts, as an ordered outcome, or by another approach.

What does a count outcome show?

A count can describe the frequency of an event or category, but its interpretation depends on what was counted and over what period. Here, the registry specifies a number of dialyzers and ratings at each treatment. It does not clarify whether one dialyzer could contribute repeated observations, how repeated treatment ratings were combined, or whether the unit for analysis was a treatment, a dialyzer, or a participant. These details affect the independence of observations and the meaning of a comparison.

In general, repeated observations from the same person or device may be related rather than independent. Treating related observations as if they were independent can make uncertainty appear smaller than it is. A suitable analysis would need to account for the actual observation structure, but the registry record does not report the statistical method or enough detail to identify that structure. This is a general statistical consideration, not a claim about the analysis used in this study.

Why might over-dispersion matter?

In general, a count model may assume a particular relationship between the average count and its variability. Over-dispersion means that observed counts vary more than the model assumes. If ignored, uncertainty estimates can be too small, making results seem more precise than they are. A model or variance method that allows for extra variation may be appropriate when the data show over-dispersion. The posted registry record provides no count results, model specification, or variability estimates, so it is not possible to assess whether over-dispersion was present or how it was handled.

What can a confidence interval tell a reader?

In general, a confidence interval describes the uncertainty around an estimated quantity under the assumptions of the analysis. A narrow interval indicates greater precision than a wide interval, but precision is not the same as absence of bias. An interval cannot correct problems from nonrandom allocation, missing observations, or an unsuitable model. The registry record does not report an interval for the primary outcome, so no statement about the precision of a device comparison can be made.

How should a p-value be read?

In general, a p-value measures how incompatible the observed data are with a specified statistical model and null hypothesis, assuming the model and analysis are appropriate. It does not measure the probability that a treatment works, and it does not describe the size or importance of an effect. A p-value also cannot repair a non-comparable study design. No p-value or primary-outcome analysis is reported in the registry record.

The registry notes 0 analyses. This means the record available for this analysis does not provide a registered analysis result to interpret. It does not establish what analyses may have been performed outside the registry record. The statistical plan, including any adjustment, model choice, handling of repeated observations, or prespecified contrast, is not reported in the registry record.

How should planning illustrations be understood?

Any sample-size figures associated with these results are planning illustrations based on an observed effect, not the trial’s original design justification. The stated illustration assumptions are a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is a stated fraction of the observed effect. For non-time-to-event outcomes, such figures are expressed as participants per arm for 80% power or another stated power level. Time-to-event planning uses a total number of events under the Schoenfeld method. These assumptions do not establish that the study itself used them.

Planning illustrations are not observed power and do not show the probability that a completed study detected a true effect. They are sensitive to the estimated effect used as their basis, and an observed effect can be unstable, particularly when results are sparse or uncertain. No numerical planning values are reported in the registry record details available for this analysis, so no particular sample-size target or interpretation can be stated.

Finally, design and analysis are connected. Because allocation is not stated and the registry warns that the arms are not a like-for-like control comparison, a statistical adjustment—if one were performed—would not automatically make the groups exchangeable. The record does not describe adjustment variables, so the possibility or adequacy of adjustment cannot be assessed.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 5 outcome measures and 0 analyses. It does not report a multiplicity plan, such as whether one outcome was designated as the sole confirmatory test, whether other outcomes were considered supportive, or whether statistical testing was adjusted for examining multiple outcomes. When multiple outcomes or contrasts are examined, the chance of at least one apparently notable result can increase. In general, a prespecified testing strategy helps readers distinguish confirmatory analyses from exploratory ones. The strategy used in this study is not reported in the registry record.

Outcome-specific missingness and analysis populations are also not described. The record does not report how many participants or treatments contributed to the primary outcome, whether ratings were missing, or how missing observations were handled. It does not state whether analyses included all enrolled participants, only participants who received a treatment, or another population. Enrollment of 33 should not be assumed to be the denominator for every outcome.

For a repeated treatment rating, missingness could occur at the treatment or participant level, and the implications would depend on why observations were absent. In general, excluding incomplete records can bias a comparison if the probability of missingness is related to treatment or outcome. The registry does not provide enough information to assess this possibility. The analysis population, missing-data assumptions, and any sensitivity analyses are not reported in the registry record.

These omissions prevent evaluation of whether the registered outcome measures were fully reported or how analytical choices affected the findings. They do not show that data were missing or that multiplicity adjustments were omitted in an analysis outside the registry; those details are simply not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 1% reporting threshold.

The adverse-event record lists 33 hemodialysis patients at risk for serious adverse events and 0 affected. It separately lists 33 at risk for other adverse events and 0 affected. These are the posted registry counts, and they should be read as recorded rather than as proof that no events occurred outside the record or that all possible safety outcomes were assessed.

The record does not report deaths; the deaths field is null. This is different from a reported count of zero deaths. No serious adverse-event terms are listed. The registry information does not give event definitions, surveillance procedures, follow-up duration, severity detail beyond the serious/non-serious distinction, or an arm-level breakdown.

The two at-risk figures are reported separately. They should not be added or treated as a count of distinct participants. Nor do the aggregate figures establish comparative safety between devices: allocation and arm-level adverse-event results are not reported, and the registry cautions that the arms are not a like-for-like control comparison.

Safety counts are descriptive. In general, a recorded zero in a limited study does not establish that an event is impossible or that risks are identical across devices. The record’s entries support only the stated counts and the limitations on their interpretation.

12. What the Result Does, and Does Not, Mean

The central meaning of the registry record is that the study was intended to describe ease of use and thrombogenicity for specified dialyzers during routine hemodialysis, with priming blood-side ease listed as the primary outcome. The rating scale gives a concrete description of what nursing staff were asked to assess, from straightforward air removal to air that could not be removed.

What the record does not establish is equally important. It does not report the primary outcome counts, a device contrast, an uncertainty interval, or an analysis result. Readers therefore cannot determine from this record how the dialyzers were rated, whether their ratings differed, or how precise any difference was. The absence of reported results should not be interpreted as evidence of no difference.

The registry also does not establish a randomized comparison. Allocation is not stated, and the record specifically cautions that the arms are not a like-for-like control comparison. Consequently, a difference between groups, if reported elsewhere, would require careful consideration of group comparability and the way treatments were assigned. The available information is insufficient to assess those issues or to attribute an outcome to the dialyzer alone.

The listed adverse-event counts are limited to the aggregate figures recorded: 0 affected for serious events and 0 affected for other events among the separately reported at-risk groups. The record does not report deaths, arm-level safety results, or the details needed to assess the scope of surveillance. These entries do not establish comparative safety.

In general, a study’s result should be judged by the outcome definition, study design, completeness of reporting, and uncertainty around estimates. Here, the outcome definition and stated study purpose are available, but the numerical primary results and analysis are not. The registry record is therefore useful for understanding what was intended to be studied, but insufficient to draw a conclusion about relative device performance or clinical effects.

13. Why This Trial Matters Statistically

This study is statistically instructive because its primary measure is a practical categorical rating recorded at each treatment, while the registry describes the unit as a number of dialyzers. That combination raises an important analysis question: what is the observation unit, and how are repeated ratings handled? Counts can be easy to report, but they do not automatically account for dependence among observations from the same participant or device.

The study also illustrates why an objective and an outcome result are not interchangeable. The registry states that ease of use and thrombogenicity were of interest and defines the priming rating, but the record does not provide numerical findings or analyses. A clearly described endpoint helps readers understand what was meant to be measured; it cannot substitute for observed data and an estimate of uncertainty.

Design information is essential to interpreting comparisons. The allocation method is not stated, and the registry cautions that the arms are not a like-for-like control comparison. These details limit what a statistical contrast could establish, regardless of how it is calculated. Statistical methods can quantify uncertainty under assumptions, but they cannot by themselves resolve group differences created by a non-comparable design.

Finally, the record separates enrollment and adverse-event counts from outcome-specific reporting. Enrollment of 33 does not identify the denominator for every endpoint, and aggregate safety counts do not establish comparative safety. These distinctions are broadly useful when reading registry records: identify the measurement unit, denominator, analysis population, design, and reported uncertainty before interpreting a result.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main trial-specific limitation is the lack of posted numerical results for the primary endpoint. The registry defines four rating categories and says ratings were intended at each treatment, but does not provide their counts or any statistical contrast. It is therefore not possible to describe the observed distribution or estimate the precision of a comparison.

The study’s allocation method is not stated. The registry explicitly cautions that this was not a randomized comparison and that the arms are not a like-for-like control comparison. Arm-level enrollment and treatment assignments are also not reported. These omissions limit causal interpretation and prevent assessment of baseline comparability.

The record does not explain how treatment-level ratings relate to participants or dialyzers, how repeated observations were summarized, or whether the same individuals contributed ratings for more than one device. The outcome-specific denominator, missing-data handling, and analysis population are not reported. Those details would be necessary to assess the count analysis and its uncertainty.

Although the study purpose mentions thrombogenicity, the available record does not report its results or define a corresponding outcome measure. It lists 5 outcome measures but provides 0 analyses. The statistical plan, multiplicity strategy, and any sensitivity analyses are not reported in the registry record.

Safety information is aggregate and limited: at-risk counts and affected counts are listed separately for serious and other adverse events, while deaths are not reported. Follow-up duration, event definitions, and arm-level safety data are absent. These limits mean the registry record can describe the study’s stated aims and selected reporting fields, but cannot support conclusions about comparative effectiveness, ease-of-use results, or comparative safety.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Ease of Use and Blood Clotting for the Gambro Polyflux HD-C4 Big Dialyzer — NCT00659724.
• Registry record last updated 2025-07-24; status last verified 2025-07.
• Results first posted 2011-06-27.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes a completed study sponsored by Vantive Health LLC, with chronic kidney failure listed as the condition. Enrollment was 33; the study start is recorded as 2008-03 and primary completion as 2008-05. The stated purpose was to collect information on ease of use and thrombogenicity for the Gambro Polyflux HD-C4 Big and Fresenius Optiflux 180NR or 200NR dialyzers during routine hemodialysis.

The primary outcome is ease of priming the blood side, rated at each treatment in four categories and expressed as a number of dialyzers. The record lists 5 outcome measures and 0 analyses, but does not report the primary outcome results or a statistical comparison. Allocation is not stated, and the record cautions that the arms are not a like-for-like control comparison.

Aggregate adverse-event counts list 0 affected for serious events and 0 affected for other events, with 33 at risk reported separately for each. Deaths are not reported. The registry record does not provide the additional outcome, analysis, allocation, or safety details needed to assess relative device performance.